These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26037015)

  • 1. Acyclovir-related kidney injury during alemtuzumab infusion.
    Bianco A; Gambaro G; Rossini PM; Mirabella M
    J Neurol; 2015 Jul; 262(7):1772-4. PubMed ID: 26037015
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
    Perumal JS; Foo F; Cook P; Khan O
    Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-glomerular basement membrane disease after alemtuzumab.
    Clatworthy MR; Wallin EF; Jayne DR
    N Engl J Med; 2008 Aug; 359(7):768-9. PubMed ID: 18703487
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab for relapsing-remitting multiple sclerosis.
    Diaz RA; Doss S; Burke MJ; George E; Adler AI
    Lancet Neurol; 2014 Sep; 13(9):869-70. PubMed ID: 25285344
    [No Abstract]   [Full Text] [Related]  

  • 5. Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab.
    El Sankari S; Dahlqvist G; Monino L; van Pesch V
    Acta Neurol Belg; 2018 Jun; 118(2):331-333. PubMed ID: 29713905
    [No Abstract]   [Full Text] [Related]  

  • 6. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes encephalitis during natalizumab treatment in multiple sclerosis.
    Kwiatkowski A; Gallois J; Bilbault N; Calais G; Mackowiak A; Hautecoeur P
    Mult Scler; 2012 Jun; 18(6):909-11. PubMed ID: 22048950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
    Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab in multiple sclerosis: an update.
    Gross RH; Krieger S
    Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancolitis a novel early complication of Alemtuzumab for MS treatment.
    Vijiaratnam N; Rath L; Xu SS; Skibina O
    Mult Scler Relat Disord; 2016 May; 7():83-4. PubMed ID: 27237765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
    Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ITP: tolerance lost.
    Fogarty PF
    Blood; 2011 Dec; 118(24):6232-4. PubMed ID: 22161847
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia.
    Roux C; Thyss A; Gari-Toussaint M
    J Mycol Med; 2013 Dec; 23(4):270-3. PubMed ID: 24210582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
    Le Page E; Deburghgraeve V; Lester MA; Cardiet I; Leray E; Edan G
    J Neurol; 2015; 262(4):1024-34. PubMed ID: 25701008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
    Blair NF; Brew BJ; Halpern JP
    Neurology; 2012 Feb; 78(7):507-8. PubMed ID: 22302545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.